Evidence map›Paper›PMID 34047002›Full record

ArticleEMBO reports2021

Lysosome positioning and mTOR activity in Lowe syndrome.

Cansu Karabiyik, Sung Min Son, David C Rubinsztein

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Mechanism of the Regulation of Plasma Cholesterol Levels by PI(4,5)PAdvances in experimental medicine and biology · 2023
    Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Cansu KarabiyikDepartment of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.ORCID 0000-0001-7993-1825
Sung Min SonDepartment of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.
David C RubinszteinDepartment of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.ORCID 0000-0001-5002-5263
University of Cambridge · GB

Funding

Medical Research Council UKDRI-2002
6 · The paper itself

Abstract

Lowe syndrome is a rare, developmental disorder caused by mutations in the phosphatase, OCRL. A study in this issue of EMBO Reports shows that OCRL is required for microtubule nucleation and that mutations in this protein lead to an inability to activate mTORC1 signaling and consequent cell proliferation in the presence of nutrients. These defects are the result of impaired microtubule-dependent lysosomal trafficking to the cell periphery and are independent of OCRL phosphatase activity.

Indexed as

Oculocerebrorenal SyndromeHumansLysosomesMutationPhosphoric Monoester HydrolasesTOR Serine-Threonine KinasesMTOR protein, humanPhosphoric Monoester HydrolasesTOR Serine-Threonine Kinases

Identifiers

PMID34047002
PMCPMC8406394
OpenAlexW3164412216

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.